Document Detail


Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases.
MedLine Citation:
PMID:  8948661     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.
Authors:
V Lévy; A Bourgarit; A Delmer; O Legrand; M Baudard; B Rio; R Zittoun
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  53     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-01-13     Completed Date:  1997-01-13     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  239-41     Citation Subset:  IM    
Affiliation:
Service d'Hématologie, Hôtel-Dieu, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Anemia / drug therapy,  etiology,  therapy
Combined Modality Therapy
Danazol / therapeutic use*
Erythrocyte Transfusion / statistics & numerical data
Female
Humans
Male
Middle Aged
Primary Myelofibrosis / complications,  drug therapy*
Splenomegaly / drug therapy,  etiology
Chemical
Reg. No./Substance:
17230-88-5/Danazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  On the value of menorrhagia as a predictor for coagulation disorders.
Next Document:  Buffer may be the critical factor in measurement of anti-prothrombin antibody on a gamma-ray-irradia...